期刊
NANO LETTERS
卷 21, 期 22, 页码 9706-9714出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.1c03539
关键词
siRNA delivery; intercalation; nanogels; RNAi; cancer therapy
类别
资金
- National Key R&D Program of China [2020YFA0908800]
- Shenzhen Science and Technology Program [KQTD20190929172538530]
- Lung Cancer Discovery Award from the American Lung Association
- Harvard Medical School/Brigham and Women's Hospital Department of Anesthesiology-Basic Scientist Grant [2420 BPA075]
- US METAvivor Early Career Investigator Award [2018A020560]
- Center for Nanomedicine Research Fund [2019A014810]
This study presents a novel approach using an intercalation-driven siRNA nanogels (NG) as a delivery vehicle, which demonstrates good stability and efficient intracellular delivery for cancer therapy.
RNA interference (RNAi) is a powerful approach in the treatment of various diseases including cancers. The clinical translation of small interfering RNA (siRNA)-based therapy requires safe and efficient delivery vehicles. Here, we report a siRNA nanogels (NG)-based delivery vehicle, which is driven directly by the intercalation between nucleic acid bis-intercalator and siRNA molecules. The intercalation-based siRNA NG exhibits good physiological stability and can enter cells efficiently via different endocytosis pathways. Furthermore, the siRNA NG can not only silence the target genes in vitro but also significantly inhibit the tumor growth in vivo. Therefore, this study provides an intercalation-based strategy for the development of a siRNA delivery platform for cancer therapy. To the best of our knowledge, this is the first report of the intercalation-driven siRNA NG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据